Efficacy and safety of drug therapies for treating tuberculous meningitis: a network meta-analysis
The Journal of Infection in Developing Countries · 30.04.2026 · 20 (04) · 477-493
DOI: 10.3855/jidc.21300 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift The Journal of Infection in Developing Countries, online erschienen am 30.04.2026. Verfasst von Mengyu Luan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Chest Hospital, Capital Medical University, No. 97 Ma Chang, Tongzhou District, Beijing of China. Hauptthemen laut MEDLINE: Tuberculosis, Meningeal, Antitubercular Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The optimal treatment for tuberculous meningitis (TBM) remains inconclusive. This study intends to compare the efficacy and safety of available drug therapies for treating TBM from the perspective of mortality, neurological events, and adverse events.
Methods
PubMed (21/6/2025), Cochrane (21/6/2025), Embase (21/6/2025), and Web of Science (21/6/2025) were searched for randomized controlled trials (RCTs) of TBM. Risk of Bias 2.0 was used for the quality assessment of the included studies. R4.2.3 "gemtc" package was used for data analysis, and Stata 15.0 was utilized to assess publication bias. Odds ratios (ORs) with 95% credible intervals (95% CrIs) were calculated as effect sizes.
Results
Twenty-nine RCTs involving 4,640 TBM patients were included. The results showed that when combined with the standard treatment, prednisone might reduce TBM mortality [OR (95% CrI) = 0.26 (0.07, 0.78)]; both methylprednisolone [OR (95% CrI) = 0.13 (0, 0.98)] and prednisone [OR (95% CrI) = 0.18 (0.02, 0.76)] were likely to reduce the incidence of tuberculoma and other extracranial tuberculosis; prednisolone might increase the risk of neurological events [OR (95% CrI) = 5.98 (2.03, 20.7)], while standard-dose rifampicin was less likely to cause neurological events [OR (95% CrI) = 0.25 (0.06, 0.78)]; dexamethasone might increase the incidence of gastrointestinal events [OR (95% CrI) = 1.72 (1.04, 2.91)]; levofloxacin was more likely to cause hepatic events [OR (95% CrI) = 1.79 (1.05, 3.14)].
Conclusions
Prednisone, levofloxacin, and linezolid, rather than high-dose rifampicin, may reduce TBM mortality compared with standard-dose rifampicin. Prednisolone increases the risk of neurological events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Chest Hospital, Capital Medical University, No. 97 Ma Chang, Tongzhou District, Beijing of China.
Zitieren
APA
Luan, M., & Chen, X. (2026). Efficacy and safety of drug therapies for treating tuberculous meningitis: a network meta-analysis. The Journal of Infection in Developing Countries, 20(04), 477-493. https://doi.org/10.3855/jidc.21300
Vancouver
Luan M, Chen X. Efficacy and safety of drug therapies for treating tuberculous meningitis: a network meta-analysis. The Journal of Infection in Developing Countries. 2026;20(04):477-493. doi:10.3855/jidc.21300
BibTeX
@article{Luan2026,
author = {Luan, Mengyu and Chen, Xiaoyou},
title = {Efficacy and safety of drug therapies for treating tuberculous meningitis: a network meta-analysis},
journal = {The Journal of Infection in Developing Countries},
year = {2026},
volume = {20},
number = {04},
pages = {477--493},
doi = {10.3855/jidc.21300}
}
EUVIMED